Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

zirconium Zr 89-DFO-REGN3504

A radioimmunoconjugate consisting of an antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon administration, the antibody moiety of zirconium Zr 89-DFO-REGN3504 specifically targets and binds to PD-L1. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:89Zr˗DFO˗REGN3504
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search